Compositions and methods for treatment of diabetes

Abstract

The present invention relates to compositions and methods for treatment and/or prevention of diabetes or pre-diabetes. In particular, the invention provides compositions and methods for the treatment and/or prevention of diabetes or pre-diabetes, based on the use of angiotensin-(1-7) peptides, functional equivalents thereof, and/or angiotensin (1-7) agonists.

1 .- 29 . (canceled) 
     
     
         30 . A method of treating diabetes comprising administering to a subject who is suffering from or susceptible to diabetes a non-peptidic angiotensin (1-7) receptor agonist, wherein the non-peptidic angiotensin (1-7) receptor agonist is a compound with the following structure: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         31 . The method of  claim 30 , wherein the angiotensin (1-7) receptor agonist is administered at an effective dose periodically at an administration interval such that at least one symptom or feature of diabetes is reduced in intensity, severity, duration, or frequency or has delayed in onset. 
     
     
         32 . The method of  claim 30 , wherein the wherein the diabetes is selected from the group consisting of type 1 diabetes, type 2 diabetes, and gestational diabetes. 
     
     
         33 . The method of  claim 30 , wherein the subject is suffering from pre-diabetes. 
     
     
         34 . The method of  claim 30 , wherein the angiotensin (1-7) receptor agonist is administered daily, twice a week, weekly, once every two weeks, once every three weeks, monthly, or at a variable interval. 
     
     
         35 . The method of  claim 30 , wherein the angiotensin (1-7) receptor agonist is administered intravenously, intradermally, orally, by inhalation, transdermally (topical), subcutaneously, and/or transmucosally. 
     
     
         36 . The method of  claim 30 , wherein the angiotensin (1-7) receptor agonist is administered at the effective dose ranging from about 1-1000 μg/kg/day. 
     
     
         37 . The method of  claim 30 , wherein the administration of the angiotensin (1-7) receptor agonist results in a 10%, 20%, 30%, 40%, or 50% reduction in fasting blood glucose levels in the subject as compared to a control. 
     
     
         38 . The method of  claim 30 , wherein the administration of angiotensin (1-7) receptor agonist reduces the fasting glucose level in the subject to less than 130 mg/dL. 
     
     
         39 . The method of  claim 30 , wherein the administration of the angiotensin (1-7) receptor agonist results in a 20% decrease in blood glucose in the subject as compared to a control. 
     
     
         40 . The method of  claim 30 , wherein the administration of the angiotensin (1-7) receptor agonist reduces the blood glucose level in the subject to less than about 200 mg/dL. 
     
     
         41 . The method of  claim 30 , wherein the administration of the angiotensin (1-7) receptor agonist reduces the blood glucose level in the subject to within the normal range. 
     
     
         42 . The method of  claim 37 , wherein the decrease or reduction of the glucose level is achieved within 1 month of treatment. 
     
     
         43 . The method of  claim 30 , wherein the angiotensin (1-7) receptor agonist is administered in combination with an anti-diabetic medication. 
     
     
         44 . The method  claim 43 , wherein anti-diabetic medication is selected from the group consisting of biguanides, thiazolidinediones's, dual PPAR agonists, secretagogues including sulphonylureas, meglitinides/glinides (K+), incretin mimetics, DPP-4 inhibitors, insulin, insulin analogs or special formulations, alpha-glucosidase inhibitors, amylin or amylin analogues, SGLT2 inhibitors, Benfluorex, Tolrestat, or combinations thereof.